NYSE To Commence Delisting Proceedings Against Scorpius Holdings, Inc
-Reuters
-Reuters
DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today reported that it received notice from the NYSE American of its determination to commence delisting proceedings of the Company's common stock from the exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low-selling price of the Company's common stock. The Company plans to appeal the determination to the Exchange's Listing Qualifications Panel, although there can be no assurance of a successful outcome. Scorpius CEO Jeff Wolf commented, "Despite recent po
Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency Autonomous humanoids designed to complement human labor and enhance productivity through 24/7 operational capabilities Beyond's Hive Mind capability allows autonomous humanoids to share and scale biomanufacturing knowledge and improve collective intelligence and operational efficiency DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced a groundbreaking strategic partnership with Beyond Imagination, Inc. ("Beyond"), a US-based developer of a
DURHAM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the first quarter ended March 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "We are successfully executing our strategy to enhance revenue and reduce costs as we seek to become cash flow positive in the near future. This quarter is indicative of this goal as we achieved a 359% increase in revenue while reducing operating expenses by 34% over the same period last year. We believe this performance reinforces the grow
DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced a significant expansion of its operational footprint in San Antonio, Texas, with the opening of its new, state-of-the-art storage and testing facility. This expansion increases Scorpius' warehouse facilities more than sevenfold, from ~3,000 square feet to ~22,000 square feet. The upgrade is in response to the growing demand for Scorpius' biomanufacturing services and the need to accommodate its expanding client base. The new facility is designed to meet or exceed industry standards with appropriate s
DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its underwritten public offering of 60,000,000 common units and/or pre-funded units in lieu thereof. Each common (or pre-funded) unit was offered at a public offering price of $0.10 per unit (inclusive of the pre-funded warrant exercise price) and consists of one share of common stock (or pre-funded warrant to purchase one share of common stock in lieu thereof) and a common warrant, for gross proceeds of $6,000,000, before deducting underwriting discounts and offering expen
DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization providing state-of-the-art large molecule contract development and manufacturing organization ("CDMO"), today applauded on-going legislative efforts within the United States Congress to bolster domestic biomanufacturing in the face of vulnerabilities from America's adversaries. The most notable legislative effort is the recent introduction of the BIOSECURE Act, which would mark a significant step forward in strengthening America's pharmaceutical supply chain and reducing dependency on foreign manufactur
DURHAM, N.C., May 15, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful validation of its microbial facilities, marking a significant milestone in the Company's operations. This validation signifies that Scorpius' microbial cleanrooms are now officially approved to manufacture current Good Manufacturing Practice (cGMP) microbial biologic drugs, underscoring the Company's commitment to quality and regulatory compliance. Scorpius facilities have already garnered considerable interest, with a backlog of bookings from client programs.
DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 60,000,000 common units and/or pre-funded units in lieu thereof. Each common (or pre-funded) unit is being offered at a public offering price of $0.10 per unit (inclusive of the pre-funded warrant exercise price) and consists of one share of common stock (or pre-funded warrant to purchase one share of common stock in lieu thereof) and a common warrant to purchase one share of common stock. The common warrants will have an exercise price
DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX) ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development. She brings more than 25 years of experience in biopharma business development and management. Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at BioReliance Corporation, part of MilliporeSigma. She was most recently Head of Commercial, North America, East with interim oversight of half of the European market. Her role included commercial oversight of biologics, vaccines, cell and gene therapies, ADCs, and
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius" or "the Company"), an integrated contract development and manufacturing organization providing state-of-the-art large molecule contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2023. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "We are executing our plan to augment sales and drive revenue, as evidenced by the $4.8 million of revenue from continuing operations that we reported in the fourth quarter of 2023. This represents a 570% increase from the third quarter of 2023, an
ARS - Scorpius Holdings, Inc. (0001476963) (Filer)
DEF 14A - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
PRE 14A - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX) ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development. She brings more than 25 years of experience in biopharma business development and management. Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at BioReliance Corporation, part of MilliporeSigma. She was most recently Head of Commercial, North America, East with interim oversight of half of the European market. Her role included commercial oversight of biologics, vaccines, cell and gene therapies, ADCs, and
4 - Scorpius Holdings, Inc. (0001476963) (Issuer)
SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)
SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da
U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 100 points on Monday. Following the market opening Monday, the Dow traded down 0.34% to 38,456.60 while the NASDAQ rose 0.11% to 17,707.96. The S&P 500 also fell, dropping, 0.12% to 5,425.29. Check This Out: Top 4 Risk Off Stocks That May Rocket Higher In Q2 Leading and Lagging SectorsCommunication services shares jumped by 0.6% on Monday. In trading on Monday, industrials shares fell by 1%. Top Headline The NY Empire State Manufacturing Index rose to -6 in June versus a reading of -15.6 in May and coming in better than market expectations of -12.50. Equities Trading UP
-Reuters
Gainers Concord Medical Services (NYSE:CCM) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million. Calidi Biotherapeutics (AMEX:CLDI) stock increased by 4.26% to $0.21. The market value of their outstanding shares is at $10.8 million. Anitra (AMEX:AZTR) shares moved upwards by 2.69% to $0.18. The market value of their outstanding shares is at $5.0 million. MAIA Biotechnology (AMEX:MAIA) stock rose 0.79% to $3.79. The company's market cap stands at $82.7 million. Emergent BioSolutions (NYSE:EBS) shares moved upwards by 0.53% to $5.59. The market value of their outstanding shares is at $292.9 million. Asensus Surg
Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency Autonomous humanoids designed to complement human labor andenhance productivity through 24/7 operational capabilitiesBeyond's Hive Mind capability allows autonomous humanoids to share and scale biomanufacturing knowledge and improve collective intelligence and operational efficiencyDURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced a groundbreaking strategic partnership with Beyond Imagination, Inc. ("Beyond"), a US-based developer of autonomou
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results. Bank of Montreal posted quarterly adjusted earnings of C$2.59 per share, missing market estimates of C$2.77 per share. The company's quarterly sales came in at C$7.988 billion missing expectations of C$8.046 billion, according to data from Benzinga Pro. Bank of Montreal shares declined 7.1% to $89.32 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) shares jumped 82.8% to $0.3799 a day after it received the nod from the U.S. Patent And Trademark O
Shares of Ooma, Inc. (NYSE:OOMA) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and issued strong guidance for the second quarter. The company also issued FY25 adjusted EPS guidance above estimates. Ooma shares jumped 17% to $9.24 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) rose 130.2% to $0.4789 in today's pre-market trading after the company announced that it received a notice of allowance for its U.S. patent application 17/572,387 titled “INTRAGASTRIC DEVICE (FOR TREATING OBESITY)” Scorpius Holdings,
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 82.9% to $0.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.9 million. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 39.58% to $0.16. The market value of their outstanding shares is at $10.2 million. The company's, Q1 earnings came out yesterday. Genetic Technologies (NASDAQ:GENE) stock rose 34.88% to $2.9. The company's market cap stands at $9.3 million. Surmodics (NASDAQ:SRDX) stock increased by 17.92% to $41.39. The market value of their outstanding shares is at $590.2 million. Ikena Oncology (NASDAQ:IKNA) stock increased by 17.33% to $1.56. The market value of their